Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Grants Fast Track Designation to PLN-101095 Plus Pembrolizumab in Solid Tumors

19 August 2026 · By · Wire by Fusion42

Published

19 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at onclive.com →

◆ Verified

Fusion42 · 19 August 2026 · Fusion42 review

The FDA has granted fast track designation to PLN-101095 in combination with pembrolizumab for treating solid tumors resistant to immune checkpoint inhibitors, advancing the ongoing phase 1a/1b FORTIFY trial.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your biotech company can capitalise on the accelerated FDA pathway for ICI-resistant solid tumor therapies by prioritising PLN-101095 clinical data advancement. The fast track opens the door for earlier patient access and funding opportunities ahead of competitors.

◆ Coverage

1 source · 19 Aug 2026

◆ Related on Wire

◆ Topics

Biotechfda-fast-trackoncologyimmune-checkpoint-inhibitorspln-101095pembrolizumab